Apeiron Biologics
Business Services · Austria · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Campus-vienna-biocenter 5, Vienna, Vienn...Phone Number
+43 18656577Website
www.apeiron-biologics.comRevenue
$7.7 MillionIndustry
About Apeiron Biologics
Is Apeiron Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Apeiron Biologics is spiking on competitors!
Funding: Get notified immidiatlly once Apeiron Biologics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Apeiron Biologics
Apeiron Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Apeiron Biologics launches new products
Click to see if Apeiron Biologics had a recent Job posting/layoffs
Earning: See what the market has to say on Apeiron Biologics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Apeiron Biologics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Apeiron Biologics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Apeiron Biologics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Apeiron Biologics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Apeiron Biologics.
Apeiron Biologics financials insights
Gather financial insights about Apeiron Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$29.9M
Apeiron Biologics Tech Stack
A closer look at the technologies used by Apeiron Biologics
Apeiron Biologics News & Media
Ligand to Acquire Apeiron Biologics, for $100M
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a San Diego, CA-based biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines, acquired Apeiron Biologics AG, a Vienna, Austria-based private biopharmaceutical company, for $100M. The acquisition will provide Ligand with the royalty rights to QARZIBA®, a commercial oncology drug marketed in 35 countries by global pharmaceutical […] The post Ligand to Acquire Apeiron Biologics, for $100MLigand to Acquire APEIRON Biologics AG for $100 Million
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a definitive agreement to acquire APEIRON Biologics AG, which holds royalty rights to QARZIBA® (dinutuximab beta) for the treatment of high-risk neuroblastoma, for $100 million in cash. In addition, Ligand will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certainAPEIRON shareholders approve new group structure geared towards enabling innovation and growth
invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline
Top Business Services Companies
Frequently Asked Questions Regarding Apeiron Biologics
Apeiron Biologics is a privately-held European biotech company based in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies and respiratory diseases.... Read More